Between 2013 and 2023, the market size per capita for hormones in dosage except contraceptives and antibiotics in El Salvador experienced fluctuations. Starting from a modest value of $2.79 in 2013, the market saw growth with minor contractions, peaking at $4.47 in 2021, before dipping slightly to reach $4.28 in 2023. The year-on-year variations over the last two years indicate a slight decline in 2022 followed by a modest recovery in 2023. Over the past five years, the compound annual growth rate (CAGR) reveals steady growth, indicating consistent demand.
Looking ahead, potential growth drivers include advancements in healthcare infrastructure and increased awareness of hormone therapies' benefits. Challenges may stem from regulatory changes and competitive market pressures. Monitoring these factors will be crucial for future market developments.
